Re-enforcing the strategy of targeting MEK/ERK signaling to overcome acquired resistance to third generation EGFR inhibitors.
作者信息
Zhao Wen, Sun Shi-Yong
机构信息
Department of Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, People's Republic of China.
Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA 30322, USA.
出版信息
Oncoscience. 2021 Aug 4;8:80-81. doi: 10.18632/oncoscience.539. eCollection 2021.
Abstract
摘要
相似文献
1
Re-enforcing the strategy of targeting MEK/ERK signaling to overcome acquired resistance to third generation EGFR inhibitors.强化靶向MEK/ERK信号传导的策略以克服对第三代EGFR抑制剂的获得性耐药。
Oncoscience. 2021 Aug 4;8:80-81. doi: 10.18632/oncoscience.539. eCollection 2021.
2
Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling.通过共同靶向MEK/ERK信号通路来管理对第三代EGFR酪氨酸激酶抑制剂的获得性耐药
Lung Cancer (Auckl). 2021 Feb 5;12:1-10. doi: 10.2147/LCTT.S293902. eCollection 2021.
3
MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib.MET 或 NRAS 扩增是第三代 EGFR 抑制剂纳喹替尼获得性耐药的机制。
Sci Rep. 2018 Jan 31;8(1):1955. doi: 10.1038/s41598-018-20326-z.
4
Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors.表皮生长因子受体酪氨酸激酶抑制剂的发展以及应对第三代表皮生长因子受体酪氨酸激酶抑制剂奥希替尼耐药的策略：传统方法与免疫检查点抑制剂
Front Oncol. 2020 Dec 18;10:602762. doi: 10.3389/fonc.2020.602762. eCollection 2020.
5
Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition.结直肠癌细胞对抗 EGFR 抗体的原发和获得性耐药都集中在 MEK/ERK 通路的激活上，联合 MEK/EGFR 抑制可以克服这种耐药性。
Clin Cancer Res. 2014 Jul 15;20(14):3775-86. doi: 10.1158/1078-0432.CCR-13-2181. Epub 2014 May 8.
6
The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy.RAF-MEK-ERK信号通路：靶向ERK以克服有效癌症治疗的障碍。
Future Med Chem. 2015;7(3):269-89. doi: 10.4155/fmc.14.143.
7
ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy.ERK 突变和扩增导致对 ERK 抑制剂治疗的耐药性。
Clin Cancer Res. 2018 Aug 15;24(16):4044-4055. doi: 10.1158/1078-0432.CCR-17-3674. Epub 2018 May 14.
8
Mechanisms of resistance to osimertinib.对奥希替尼的耐药机制。
J Thorac Dis. 2020 May;12(5):2851-2858. doi: 10.21037/jtd.2019.08.30.
9
Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.持续表皮生长因子受体（EGFR）抑制的疗效以及刺猬信号通路（Hedgehog）在具有EGFR激活突变的人肺癌细胞EGFR获得性耐药中的作用
Oncotarget. 2017 Apr 4;8(14):23020-23032. doi: 10.18632/oncotarget.15479.
10
A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group.AME肺癌协作组关于奥希替尼在非小细胞肺癌中作用的共识。
J Thorac Dis. 2018 Jul;10(7):3909-3921. doi: 10.21037/jtd.2018.07.61.
引用本文的文献
1
The novel BET degrader, QCA570, is highly active against the growth of human NSCLC cells and synergizes with osimertinib in suppressing osimertinib-resistant EGFR-mutant NSCLC cells.新型 BET 降解剂 QCA570 对人非小细胞肺癌（NSCLC）细胞的生长具有高度活性，并与奥希替尼协同作用，抑制奥希替尼耐药的表皮生长因子受体（EGFR）突变型 NSCLC 细胞。
Am J Cancer Res. 2022 Feb 15;12(2):779-792. eCollection 2022.
本文引用的文献
1
Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling.通过共同靶向MEK/ERK信号通路来管理对第三代EGFR酪氨酸激酶抑制剂的获得性耐药
Lung Cancer (Auckl). 2021 Feb 5;12:1-10. doi: 10.2147/LCTT.S293902. eCollection 2021.
2
Cancer Statistics, 2021.癌症统计数据，2021.
CA Cancer J Clin. 2021 Jan;71(1):7-33. doi: 10.3322/caac.21654. Epub 2021 Jan 12.
3
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.塔顿：奥希替尼联合塞来替尼、索凡替尼或度伐鲁单抗治疗 EGFR 突变型肺癌的多臂 Ib 期试验。
Ann Oncol. 2020 Apr;31(4):507-516. doi: 10.1016/j.annonc.2020.01.013. Epub 2020 Jan 24.
4
ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.ERK 抑制可有效克服表皮生长因子受体突变型非小细胞肺癌细胞对奥希替尼的获得性耐药。
Cancer. 2020 Mar 15;126(6):1339-1350. doi: 10.1002/cncr.32655. Epub 2019 Dec 10.
5
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.奥希替尼治疗未经治疗的 EGFR 突变型晚期非小细胞肺癌。
N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.
6
Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation.通过调节 MEK/ERK 依赖性 Bim 和 Mcl-1 的降解克服第三代 EGFR 抑制剂 AZD9291 的获得性耐药。
Clin Cancer Res. 2017 Nov 1;23(21):6567-6579. doi: 10.1158/1078-0432.CCR-17-1574. Epub 2017 Aug 1.
7
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.奥希替尼或铂类培美曲塞用于治疗表皮生长因子受体T790M阳性肺癌
N Engl J Med. 2017 Feb 16;376(7):629-640. doi: 10.1056/NEJMoa1612674. Epub 2016 Dec 6.
Zotero 插件